Breast cancer with bone metastasis: Molecular insights and clinical management

Abstract

Despite the remarkable advances in the diagnosis and treatment of breast cancer patients, the presence or development of metastasis remains an incurable condition. Bone is one of the most frequent sites of distant dissemination and negatively impacts on patient’s survival and overall frailty. The interplay between tumor cells and the bone microenvironment induces bone destruction and tumor progres-sion. To date, the clinical management of bone metastatic breast cancer encompasses anti‐tumor systemic therapies along with bone‐targeting agents, aimed at slowing bone resorption to reduce the risk of skel-etal‐related events. However, their effect on patients’ survival remains controversial. Unraveling the biology that governs the interplay between breast neoplastic cells and bone tissue would provide means for the development of new therapeutic agents. This article outlines the state‐of‐the art in the characterization and targeting the bone metastasis in breast cancer, focusing on the major clinical and translational studies on this clinically relevant topic.